Roche

News

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.

News

Reviews underway of first drug for rare disease MOGAD

Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.

News

Person holds hand of elderly lady; grey colour scheme

Major trial of Roche Alzheimer's drug kicks off in Europe

The PrevenTRON trial of Roche's Brainshuttle drug trontinemab in preclinical Alzheimer's disease has gotten underway in the UK.

News

Enhertu OK ends 10-year EU gap in frontline breast cancer

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

News

Roche taps Simcere for autoimmune trispecific for $1.53bn

Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.

News

FDA greenlights Roche’s biomarker blood test for Alzheimer's

Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care.

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

Reviews underway of first drug for rare disease MOGAD

Major trial of Roche Alzheimer's drug kicks off in Europe

Enhertu OK ends 10-year EU gap in frontline breast cancer

Roche taps Simcere for autoimmune trispecific for $1.53bn

FDA greenlights Roche’s biomarker blood test for Alzheimer's

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks